加载中
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
前收盘价
US$4.79
+US$0.13 · +2.79%
盘中时间采用ET。市场数据可能有所延迟。
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
日内区间
当前US$4.79
52周区间
当前US$4.79
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
37
偏贵
情绪
41
多空交织
风险
54
风险偏高
动量
62
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
日内区间
当前US$4.79
52周区间
当前US$4.79
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1866.6万 USD | 2639.1万 USD | 3416.4万 USD | 5907.7万 USD | 3474.8万 USD |
| 销货成本 | 2205.7万 USD | — | — | — | — |
| 毛利 | −339.1万 USD | 2639.1万 USD | 3416.4万 USD | 5907.7万 USD | 3474.8万 USD |
| 研究与开发 | 4775.4万 USD | 5511万 USD | 5652.5万 USD | 4836.4万 USD | 3923.2万 USD |
| 销售、一般及管理费用 | 2921.5万 USD | 3074.1万 USD | 3331.3万 USD | 2490.3万 USD | 1694.7万 USD |
| 营业费用 | 6812.7万 USD | 1.01亿 USD | 1.04亿 USD | 8572.5万 USD | 7035.7万 USD |
| 利息收入 | 266万 USD | 310.6万 USD | 505.5万 USD | 58.7万 USD | — |
| 利息支出 | — | — | — | — | 7000 USD |
| 折旧和摊销 | 2175.4万 USD | 2358.3万 USD | 1949.7万 USD | 1824.9万 USD | 1625.2万 USD |
| 营业利润 | −7151.8万 USD | −7450.2万 USD | −6941.9万 USD | −2664.8万 USD | −3560.9万 USD |
| 净利润 | −6477.9万 USD | −6203.3万 USD | −5061.9万 USD | −2233.4万 USD | −2704.2万 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1355.13万0.02%787.4亿 USD0.19%US$278.94—
Vanguard Morningstar Total Stock Market ETFVTI1042.32万0.00%2.3万亿 USD0.03%US$381.94—
Vanguard Extended Market ETFVXF611.98万0.01%954亿 USD0.05%US$235—
iShares Biotechnology ETFIBB433.68万0.04%108.2亿 USD0.44%US$206.49—
Schwab U.S. Small-Cap ETFSCHA280.48万0.01%218.24亿 USD0.03%US$32.79—
Vanguard Russell 2000 ETFVTWO277.02万0.02%180亿 USD0.06%US$112.66—
iShares Micro-Cap ETFIWC161.88万0.12%13.17亿 USD0.60%US$183—
Dimensional - US Small Cap ETFDFAS152.71万0.00%338.69亿 USD0.31%US$78.35—iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
